157 related articles for article (PubMed ID: 24029220)
1. Pulmonary exacerbations in CF patients with early lung disease.
Anstead M; Saiman L; Mayer-Hamblett N; Lands LC; Kloster M; Goss CH; Rose L; Burns JL; Marshall B; Ratjen F
J Cyst Fibros; 2014 Jan; 13(1):74-9. PubMed ID: 24029220
[TBL] [Abstract][Full Text] [Related]
2. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
3. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
[TBL] [Abstract][Full Text] [Related]
4. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.
Mayer-Hamblett N; Saiman L; Lands LC; Anstead M; Rosenfeld M; Kloster M; Fisher L; Ratjen F
Contemp Clin Trials; 2013 Sep; 36(1):99-105. PubMed ID: 23770109
[TBL] [Abstract][Full Text] [Related]
5. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of azithromycin in patients with cystic fibrosis.
Samson C; Tamalet A; Thien HV; Taytard J; Perisson C; Nathan N; Clement A; Boelle PY; Corvol H
Respir Med; 2016 Aug; 117():1-6. PubMed ID: 27492507
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE; Schechter MS; Wagener JS; Morgan WJ; Pasta DJ; Elkin EP; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):649-57. PubMed ID: 22949088
[TBL] [Abstract][Full Text] [Related]
8. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary exacerbations in cystic fibrosis.
Stenbit AE; Flume PA
Curr Opin Pulm Med; 2011 Nov; 17(6):442-7. PubMed ID: 21881509
[TBL] [Abstract][Full Text] [Related]
10. Changes in lung function measured by spirometry and the forced oscillation technique in cystic fibrosis patients undergoing treatment for respiratory tract exacerbation.
Ren CL; Brucker JL; Rovitelli AK; Bordeaux KA
Pediatr Pulmonol; 2006 Apr; 41(4):345-9. PubMed ID: 16496336
[TBL] [Abstract][Full Text] [Related]
11. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
[TBL] [Abstract][Full Text] [Related]
13. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations.
Newport S; Amin N; Dozor AJ
Pediatr Pulmonol; 2009 Sep; 44(9):866-72. PubMed ID: 19670404
[TBL] [Abstract][Full Text] [Related]
14. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin for improving pulmonary function in cystic fibrosis.
Carr RR; Nahata MC
Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
[TBL] [Abstract][Full Text] [Related]
16. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
17. Long term azithromycin therapy in patients with cystic fibrosis.
Emiralioğlu N; Öztürk Z; Yalçın E; Doğru D; Özçelik U; Kiper N
Turk J Pediatr; 2016; 58(1):34-40. PubMed ID: 27922234
[TBL] [Abstract][Full Text] [Related]
18. Objective monitoring of cough in children with cystic fibrosis.
Hamutcu R; Francis J; Karakoc F; Bush A
Pediatr Pulmonol; 2002 Nov; 34(5):331-5. PubMed ID: 12357476
[TBL] [Abstract][Full Text] [Related]
19. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.
Amin R; Lam M; Dupuis A; Ratjen F
Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727
[TBL] [Abstract][Full Text] [Related]
20. Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.
Denis A; Touzet S; Diabaté L; Durieu I; Lemonnier L; Poupon-Bourdy S; Iwaz J; Reynaud Q; Rabilloud M
Ann Am Thorac Soc; 2020 Feb; 17(2):195-201. PubMed ID: 31604024
[No Abstract] [Full Text] [Related]
[Next] [New Search]
